Increasing Progesterone Levels Are Associated With Smoking Abstinence Among Free-Cycling Women Smokers Who Receive Brief Pharmacotherapy
- 10 March 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 17 (4) , 398-406
Abstract
Preclinical and human laboratory research suggests that (a) progesterone may decrease drug reward, craving, and smoking behavior, and (b) estradiol may enhance drug reward and smoking behavior. A modest majority of treatment research examining the relationship between menstrual cycle phase and outcomes suggests that the luteal menstrual phase, with its uniquely higher progesterone levels, is associated with better cessation outcomes. However, no studies to date have examined the effects of naturally occurring variation in progesterone and estradiol levels on medication-assisted smoking cessation. The present study sought to fill this notable gap in the treatment literature. Weekly plasma progesterone and estradiol levels were obtained from nicotine-dependent female smokers enrolled in a 4-week cessation trial. Participants (N = 108) were randomized to receive a 4-week course of either varenicline (VAR) tablets and placebo patches or placebo tablets and nicotine patches. Plasma samples were obtained 1 week before their cessation attempt and weekly during medication administration. Abstinence was assessed weekly. Weekly hormone data replicated commonly observed menstrual cycle patterns of progesterone and estradiol levels. Importantly, increases in progesterone level were associated with a 23% increase in the odds for being abstinent within each week of treatment. This effect was driven primarily by nicotine patch–treated versus VAR-treated females. This study was the first to identify an association between progesterone level (increasing) and abstinence outcomes in free-cycling women smokers who participated in a medication-based treatment. Furthermore, the potential benefits of progesterone may vary across different pharmacotherapies. Implications of these findings for smoking cessation intervention are discussed.Keywords
This publication has 59 references indexed in Scilit:
- Association between ovarian hormones and smoking behavior in women.Experimental and Clinical Psychopharmacology, 2012
- Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropionDrug and Alcohol Dependence, 2011
- Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokersPsychoneuroendocrinology, 2011
- The role of progestins in the behavioral effects of cocaine and other drugs of abuse: Human and animal researchNeuroscience & Biobehavioral Reviews, 2010
- Does the response to cocaine differ as a function of sex or hormonal status in human and non-human primates?Hormones and Behavior, 2010
- Sex and ovarian hormones influence vulnerability and motivation for nicotine during adolescence in ratsPharmacology Biochemistry and Behavior, 2009
- Patterns of self-selected smoking cessation attempts and relapse by menstrual phaseAddictive Behaviors, 2009
- Progesterone effects on subjective and physiological responses to intravenous nicotine in male and female smokersHuman Psychopharmacology: Clinical and Experimental, 2009
- Interactions among ovarian hormones and time of testing on behavioral sensitization and cocaine self-administrationBehavioural Brain Research, 2007
- Robust Locally Weighted Regression and Smoothing ScatterplotsJournal of the American Statistical Association, 1979